美国糖尿病酮酸症治疗市场规模、份额和趋势分析报告：按疗法、最终用途、地区和细分市场预测，2025 年至 2033 年

市场规模和趋势

预计 2024 年美国糖尿病酮酸症治疗市场规模为 2.6143 亿美元，到 2033 年将达到 3.7439 亿美元，2025 年至 2033 年的复合年增长率为 4.07%。

这一增长是由美国人口整体中第1型糖尿病和胰岛素依赖型2型糖尿病盛行率的上升所驱动。这种增长导致与急性糖尿病併发症（尤其是糖尿病酮酸症）相关的住院人数增加。人们越来越意识到早期糖尿病酮症酸中毒管理和及时介入的重要性，这也促进了这一增长。

急救基础设施的进步以及速效胰岛素治疗和输液的普及进一步推动了这种扩张。例如，2025年1月，《印度重症监护医学杂誌》在PubMed上发表了一篇综述文章（PMID：39802248），显示平衡电解质溶液可使成年糖尿病酮症酸中毒 (DKA) 患者的碳酸氢盐水平升高1.63 mmol/L，氯化物水平降低2.37 mmol/L。标准化医院治疗通讯协定的日益普及正在改善美国医疗机构对糖尿病酮酸症的管理。医院正在采用结构化的指南，概述输液、胰岛素治疗和电解质矫正，以确保及时一致的治疗。例如，2023年12月，美国糖尿病协会在《糖尿病护理》杂誌上发表了“2024年糖尿病护理标准”，重点介绍了管理糖尿病酮症酸中毒和高血糖高血脂状态的最新指南。该指南强调液体、胰岛素和电解质治疗的结构化方案，目的是减少治疗的变异性并改善美国医疗保健的患者预后。

长效胰岛素类似物可实现更稳定的血糖控制并减少给药频率，从而降低出院后糖尿病酮症酸中毒 (DKA) 復发的风险。速效静脉胰岛素製剂对于急诊急性发作的有效管理仍然至关重要。胰岛素製剂与其他降血糖药物的联合治疗因其在復健和长期管理中的显着益处而备受关注。例如，美国儿科药学协会于2024年12月发表了一项题为「糖尿病酮酸中毒危重病患儿早期与晚期启动长效胰岛素的回顾性比较」(PMCID: PMC11627569) 的研究。研究纳入了233例病例，发现早期和晚期启动Insulin Glargine治疗在酸中毒缓解时间、住院时长或併发症发生率方面均无显着差异。结果表明，启动时间并不影响儿童DKA治疗的临床疗效。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国糖尿病酮酸症治疗市场变数、趋势与范围

• 市场体系展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 商业环境分析
  • 产业分析—波特五力分析
  • PESTLE分析
  • 管道分析
  • 专利到期分析
  • 定价分析

第四章美国糖尿病酮酸症治疗市场：治疗业务分析

• 2024年和2033年的治疗市场占有率
• 治疗细分仪表板
• 市场规模、预测与趋势分析（按治疗，2021-2033 年）
• 液体替代疗法
• 电解质替代疗法
• 胰岛素治疗
• 其他的

第五章美国糖尿病酮酸症治疗市场：最终用途业务分析

• 2024年和2033年的最终用途市场占有率
• 最终用途细分仪表板
• 按最终用途分類的市场规模、预测和趋势分析（2021-2033 年）
• 医院
• 门诊手术中心（ASC）
• 居家照护

第六章 竞争态势

• 参与者概览
• 企业市场分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • Pfizer Inc.
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Hikma Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Fresenius Kabi
  • Biocon

Market Size & Trends:

The U.S. diabetic ketoacidosis treatment market size was estimated at USD 261.43 million in 2024 and is projected to reach USD 374.39 million by 2033, growing at a CAGR of 4.07% from 2025 to 2033. This growth is driven by the increasing incidence of type 1 and insulin-dependent type 2 diabetes across the U.S. population. This rise has led to higher hospital admissions related to acute diabetic complications, particularly diabetic ketoacidosis. This growth is also supported by greater awareness of early DKA management and the importance of timely intervention.

This expansion is further fueled by advancements in emergency care infrastructure and the availability of rapid-acting insulin therapies and intravenous fluid solutions. For instance, in January 2025, the Indian Journal of Critical Care Medicine published a review on PubMed (PMID: 39802248) showing that balanced electrolyte solutions increased bicarbonate by 1.63 mmol/L and reduced chloride by 2.37 mmol/L in adult DKA patients. The increasing adoption of standardized hospital treatment protocols is improving the management of diabetic ketoacidosis across U.S. healthcare facilities. Hospitals utilize structured guidelines outlining fluid replacement, insulin therapy, and electrolyte correction to ensure timely and consistent care. For instance, in December 2023, the American Diabetes Association published its Standards of Care in Diabetes 2024 in Diabetes Care, highlighting updated guidelines for managing diabetic ketoacidosis and hyperglycemic hyperosmolar state. The guidance emphasized structured protocols for fluid, insulin, and electrolyte therapy. It aimed to reduce treatment variability and improve patient outcomes across U.S. healthcare settings.

Pharmaceutical advancements in insulin therapy are significantly strengthening the diabetic ketoacidosis treatment landscape in the U.S. Long-acting insulin analogs enable more stable glycemic control and reduce the frequency of administration, lowering the risk of DKA recurrence after discharge. Rapid-acting intravenous insulin formulations remain critical in emergency care settings for managing acute episodes effectively. Combination treatment options, including insulin and other glucose-lowering agents, are gaining attention for their extended benefits in recovery and long-term management. For instance, in December 2024, the Pediatric Pharmacy Association published a study titled Retrospective Comparison of Early Versus Late Initiation of Long-Acting Insulin in Critically Ill Pediatric Patients in Diabetic Ketoacidosis (PMCID: PMC11627569). It reviewed 233 cases and found no significant difference in acidosis resolution time, hospital stay, or complication rates between early and late insulin glargine initiation. The results indicated that timing did not affect clinical outcomes in pediatric DKA care.

U.S. Diabetic Ketoacidosis Treatment Market Report Segmentation

This report forecasts revenue growth for the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. diabetic ketoacidosis treatment market report based on treatment, and end use:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• Fluid Replacement Therapy
• Electrolyte Replacement Therapy
• Insulin Therapy
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Diabetic Ketoacidosis Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Diabetic Ketoacidosis Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2033
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
• 4.4. Fluid Replacement Therapy
  • 4.4.1. Fluid Replacement Therapy Market, 2021 - 2033 (USD Million)
• 4.5. Electrolyte Replacement Therapy
  • 4.5.1. Electrolyte Replacement Therapy Market, 2021 - 2033 (USD Million)
• 4.6. Insulin Therapy
  • 4.6.1. Insulin Therapy Market, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Diabetic Ketoacidosis Treatment Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
• 5.5. Ambulatory Surgical Centers (ASCs)
  • 5.5.1. Ambulatory Surgical Centers (ASCs) Market, 2021 - 2033 (USD Million)
• 5.6. Homecare Settings
  • 5.6.1. Homecare Settings Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Novo Nordisk
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Treatment Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Eli Lilly and Company
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Treatment Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Sanofi
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Treatment Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Pfizer Inc.
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Treatment Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Baxter International Inc.
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Treatment Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. B. Braun Melsungen AG
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Treatment Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. Hikma Pharmaceuticals
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Treatment Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Teva Pharmaceutical Industries Ltd.
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Treatment Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Fresenius Kabi
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Treatment Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Biocon
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Treatment Benchmarking
    • 6.5.10.4. Strategic Initiatives

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. U.S. diabetic ketoacidosis treatment market, by treatment, 2021 - 2033 (USD Million)
• Table 4. U.S. diabetic ketoacidosis treatment market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 U.S. diabetic ketoacidosis treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Competitive landscape
• Fig. 10 U.S. diabetic ketoacidosis treatment market dynamics
• Fig. 11 U.S. diabetic ketoacidosis treatment market: Porter's five forces analysis
• Fig. 12 U.S. diabetic ketoacidosis treatment market: PESTLE analysis
• Fig. 13 Treatment market, 2021 - 2033 (USD Million)
• Fig. 14 Fluid replacement therapy market, 2021 - 2033 (USD Million)
• Fig. 15 Electrolyte replacement therapy market, 2021 - 2033 (USD Million)
• Fig. 16 Insulin therapy market, 2021 - 2033 (USD Million)
• Fig. 17 Others market, 2021 - 2033 (USD Million)
• Fig. 18 End Use market, 2021 - 2033 (USD Million)
• Fig. 19 Hospitals market, 2021 - 2033 (USD Million)
• Fig. 20 Ambulatory surgical centers (ASCs) market, 2021 - 2033 (USD Million)
• Fig. 21 Homecare settings market, 2021 - 2033 (USD Million)
• Fig. 22 Company categorization
• Fig. 23 Company market position analysis
• Fig. 24 Strategic framework